A Phase II Study of Tepotinib (MSC2156119J) in Patients with solid cancers harboring c-MET amplification or exon 14 mutation Who Progressed after Standard treatment for Metastatic disease
Latest Information Update: 02 Jul 2024
At a glance
- Drugs Tepotinib (Primary)
- Indications Advanced breast cancer; Colorectal cancer; Gastric cancer; Head and neck cancer; Liver cancer; Non-small cell lung cancer; Renal cell carcinoma; Solid tumours
- Focus Therapeutic Use
- Acronyms KM-08
Most Recent Events
- 04 Jun 2024 Results assessing plasma ctDNA as a potential biomarker in MET-dysregulated advanced cancer patients with tepotinib treatment, presented at the 60th Annual Meeting of the American Society of Clinical Oncology
- 24 Oct 2023 Results (n=35) assessing the efficacy and safety of tepotinib in patients with various solid cancers harboring MET exon 14 skipping mutation (METex14) or MET gene amplification, presented at the 48th European Society for Medical Oncology Congress.
- 05 Feb 2020 New trial record